Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis

M. Tabone, L. Vigano', A. Ferrero, R. Pellerito, P. Carbonatto, L. Capussotti

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aim: To evaluate the impact of postoperative injection into the hepatic artery of 131-iodine-labeled lipiodol on disease-free and overall survival rates in patients who underwent liver surgical resection for hepatocellular carcinoma. Methods: Ten consecutive patients with HCV (hepatitis C virus)-related cirrhosis who underwent liver surgical resection for hepatocellular carcinoma were treated with adjuvant injection of 131-iodine-labeled lipiodol. They were matched with 20 HCV-positive cirrhotic controls who underwent liver resection alone; patients were paired in terms of age, Child-Pugh class, tumor size, microscopic vascular invasion, tumor histological pattern, presence of satellite nodules and type of surgical resection. Recurrence was defined as the development of a new hypervascularizated nodule in the liver. Results: No significant differences were found between the two groups in clinical, biologic and histologic characteristics, except a lower platelet count in the control group. None of the treated patients developed an intrahepatic recurrence until the 15th month from liver resection, whereas recurrences occurred in nine of the 20 patients in the control group (p = 0.01). From 18 months onwards, recurrences appeared also in the treated patients, and after 36 months of follow-up both recurrence rate and overall survival were not significantly different between the two groups. Conclusions: Intrahepatic injection of 131-iodine-labeled lipiodol improves the disease-free survival rate following liver resection of hepatocellular carcinoma in the short term up to 15 months; this advantage fades, however, away after 36 months.

Original languageEnglish
Pages (from-to)61-66
Number of pages6
JournalEuropean Journal of Surgical Oncology
Volume33
Issue number1
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Ethiodized Oil
Hepacivirus
Hepatocellular Carcinoma
Fibrosis
Recurrence
Liver
Iodine
Survival Rate
Injections
Disease-Free Survival
Control Groups
Hepatic Artery
Platelet Count
Blood Vessels
Neoplasms

Keywords

  • 131-Iodine labeled lipiodol
  • Hepatocellular carcinoma
  • Liver resection
  • Liver surgery
  • Recurrence

ASJC Scopus subject areas

  • Oncology
  • Surgery

Cite this

Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis. / Tabone, M.; Vigano', L.; Ferrero, A.; Pellerito, R.; Carbonatto, P.; Capussotti, L.

In: European Journal of Surgical Oncology, Vol. 33, No. 1, 02.2007, p. 61-66.

Research output: Contribution to journalArticle

@article{2657eee75ab7484a8b141392bc265e8c,
title = "Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis",
abstract = "Aim: To evaluate the impact of postoperative injection into the hepatic artery of 131-iodine-labeled lipiodol on disease-free and overall survival rates in patients who underwent liver surgical resection for hepatocellular carcinoma. Methods: Ten consecutive patients with HCV (hepatitis C virus)-related cirrhosis who underwent liver surgical resection for hepatocellular carcinoma were treated with adjuvant injection of 131-iodine-labeled lipiodol. They were matched with 20 HCV-positive cirrhotic controls who underwent liver resection alone; patients were paired in terms of age, Child-Pugh class, tumor size, microscopic vascular invasion, tumor histological pattern, presence of satellite nodules and type of surgical resection. Recurrence was defined as the development of a new hypervascularizated nodule in the liver. Results: No significant differences were found between the two groups in clinical, biologic and histologic characteristics, except a lower platelet count in the control group. None of the treated patients developed an intrahepatic recurrence until the 15th month from liver resection, whereas recurrences occurred in nine of the 20 patients in the control group (p = 0.01). From 18 months onwards, recurrences appeared also in the treated patients, and after 36 months of follow-up both recurrence rate and overall survival were not significantly different between the two groups. Conclusions: Intrahepatic injection of 131-iodine-labeled lipiodol improves the disease-free survival rate following liver resection of hepatocellular carcinoma in the short term up to 15 months; this advantage fades, however, away after 36 months.",
keywords = "131-Iodine labeled lipiodol, Hepatocellular carcinoma, Liver resection, Liver surgery, Recurrence",
author = "M. Tabone and L. Vigano' and A. Ferrero and R. Pellerito and P. Carbonatto and L. Capussotti",
year = "2007",
month = "2",
doi = "10.1016/j.ejso.2006.10.039",
language = "English",
volume = "33",
pages = "61--66",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Prevention of intrahepatic recurrence by adjuvant 131iodine-labeled lipiodol after resection for hepatocellular carcinoma in HCV-related cirrhosis

AU - Tabone, M.

AU - Vigano', L.

AU - Ferrero, A.

AU - Pellerito, R.

AU - Carbonatto, P.

AU - Capussotti, L.

PY - 2007/2

Y1 - 2007/2

N2 - Aim: To evaluate the impact of postoperative injection into the hepatic artery of 131-iodine-labeled lipiodol on disease-free and overall survival rates in patients who underwent liver surgical resection for hepatocellular carcinoma. Methods: Ten consecutive patients with HCV (hepatitis C virus)-related cirrhosis who underwent liver surgical resection for hepatocellular carcinoma were treated with adjuvant injection of 131-iodine-labeled lipiodol. They were matched with 20 HCV-positive cirrhotic controls who underwent liver resection alone; patients were paired in terms of age, Child-Pugh class, tumor size, microscopic vascular invasion, tumor histological pattern, presence of satellite nodules and type of surgical resection. Recurrence was defined as the development of a new hypervascularizated nodule in the liver. Results: No significant differences were found between the two groups in clinical, biologic and histologic characteristics, except a lower platelet count in the control group. None of the treated patients developed an intrahepatic recurrence until the 15th month from liver resection, whereas recurrences occurred in nine of the 20 patients in the control group (p = 0.01). From 18 months onwards, recurrences appeared also in the treated patients, and after 36 months of follow-up both recurrence rate and overall survival were not significantly different between the two groups. Conclusions: Intrahepatic injection of 131-iodine-labeled lipiodol improves the disease-free survival rate following liver resection of hepatocellular carcinoma in the short term up to 15 months; this advantage fades, however, away after 36 months.

AB - Aim: To evaluate the impact of postoperative injection into the hepatic artery of 131-iodine-labeled lipiodol on disease-free and overall survival rates in patients who underwent liver surgical resection for hepatocellular carcinoma. Methods: Ten consecutive patients with HCV (hepatitis C virus)-related cirrhosis who underwent liver surgical resection for hepatocellular carcinoma were treated with adjuvant injection of 131-iodine-labeled lipiodol. They were matched with 20 HCV-positive cirrhotic controls who underwent liver resection alone; patients were paired in terms of age, Child-Pugh class, tumor size, microscopic vascular invasion, tumor histological pattern, presence of satellite nodules and type of surgical resection. Recurrence was defined as the development of a new hypervascularizated nodule in the liver. Results: No significant differences were found between the two groups in clinical, biologic and histologic characteristics, except a lower platelet count in the control group. None of the treated patients developed an intrahepatic recurrence until the 15th month from liver resection, whereas recurrences occurred in nine of the 20 patients in the control group (p = 0.01). From 18 months onwards, recurrences appeared also in the treated patients, and after 36 months of follow-up both recurrence rate and overall survival were not significantly different between the two groups. Conclusions: Intrahepatic injection of 131-iodine-labeled lipiodol improves the disease-free survival rate following liver resection of hepatocellular carcinoma in the short term up to 15 months; this advantage fades, however, away after 36 months.

KW - 131-Iodine labeled lipiodol

KW - Hepatocellular carcinoma

KW - Liver resection

KW - Liver surgery

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=33846394107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846394107&partnerID=8YFLogxK

U2 - 10.1016/j.ejso.2006.10.039

DO - 10.1016/j.ejso.2006.10.039

M3 - Article

C2 - 17175128

AN - SCOPUS:33846394107

VL - 33

SP - 61

EP - 66

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 1

ER -